Advanced Liver Cancer with Portal Vein Involvement — Specialized Treatment in Shanghai
Portal vein tumor thrombus (PVTT) — the invasion of liver cancer into the portal vein — represents one of the most challenging scenarios in hepatocellular carcinoma management. It is associated with rapid tumor progression, increased risk of intrahepatic spread, and significantly worse prognosis. Many treatment centers consider PVTT a contraindication to surgery or locoregional therapy. At Renji Hospital in Shanghai, Dr. Wang Tao specializes in precisely this complex situation — bringing surgical and minimally invasive interventional expertise to patients who have often been told their options are limited.
Featured Specialist: Dr. Wang Tao (王涛)
Dr. Wang Tao is Associate Chief Physician in the Department of Interventional Oncology at Renji Hospital, Shanghai Jiao Tong University School of Medicine. He works within one of China's highest-volume interventional oncology programs, alongside Chief Physician Dr. Xu Aimin and Deputy Director Dr. Shi Yaoping.
Dr. Wang's clinical expertise is focused on:
- Surgery and minimally invasive ablation for complex liver cancer — including cases with portal vein tumor thrombus (PVTT) that are beyond the reach of standard interventional protocols
- Comprehensive minimally invasive interventional treatment of liver tumors — integrating ablation, TACE, and HAIC in individualized sequences
- In-depth research in the field of comprehensive minimally invasive interventional treatment of liver tumors
Portal Vein Tumor Thrombus (PVTT): Why It Matters
The portal vein is the main blood vessel supplying the liver. When HCC invades the portal vein, it creates a tumor thrombus — a mass of cancer cells within the vessel — that has several serious consequences:
- Increased intrahepatic spread: Portal blood flow carries tumor cells throughout the liver, seeding new tumor deposits
- Portal hypertension: Obstruction of portal flow raises pressure in the portal system, worsening ascites and variceal bleeding risk
- Contraindication to TACE: Standard TACE is often contraindicated when main portal vein flow is compromised, as embolization can precipitate liver failure
- Reduced surgical eligibility: PVTT significantly increases the complexity and risk of hepatic resection
- Worse prognosis: Median survival without treatment is 2–4 months; even with systemic therapy, outcomes are significantly worse than HCC without PVTT
Despite these challenges, selected patients with PVTT can benefit substantially from aggressive multimodal treatment — and Dr. Wang's expertise is in identifying and treating these patients.
Treatment Approaches for HCC with PVTT
Surgical Resection with Thrombectomy
- For patients with resectable primary tumor and PVTT confined to first-order portal vein branches, surgical resection combined with portal vein thrombectomy can achieve R0 resection
- Requires careful patient selection based on liver function reserve, tumor extent, and performance status
- Can achieve median survival of 12–20 months in selected patients — significantly better than non-surgical approaches
- Dr. Wang coordinates with hepatobiliary surgery for combined surgical-interventional planning
Hepatic Arterial Infusion Chemotherapy (HAIC)
- HAIC with FOLFOX regimen is one of the most effective treatments for HCC with PVTT
- Unlike TACE, HAIC does not require complete arterial embolization and can be used even with compromised portal flow
- Response rates of 20–40% have been reported, with some patients achieving sufficient downstaging for subsequent surgery or transplantation
- Combination with PD-1 inhibitors (sintilimab, camrelizumab) and targeted therapy (lenvatinib) further improves outcomes
Minimally Invasive Ablation
- Microwave ablation (MWA): For smaller tumor components or residual disease after TACE/HAIC, ablation can achieve local tumor control
- Irreversible electroporation (IRE): Non-thermal ablation technique that can be used near major vessels without the heat-sink effect — particularly relevant for perivascular tumors adjacent to the portal vein
- Percutaneous or laparoscopic approach: Selected based on tumor location and patient condition
Stereotactic Body Radiation Therapy (SBRT) for PVTT
- High-dose focused radiation to the portal vein tumor thrombus can achieve thrombus regression and portal vein recanalization
- Dr. Wang coordinates with radiation oncology for combined interventional + SBRT protocols
- Thrombus regression after SBRT may restore TACE eligibility
Combination Systemic Therapy
- Atezolizumab + bevacizumab (IMbrave150 regimen) — first-line standard for advanced HCC including PVTT
- Sintilimab + bevacizumab biosimilar — domestically approved combination with comparable efficacy
- Lenvatinib monotherapy — effective for HCC with PVTT, with higher response rates than sorafenib
- Combination of systemic therapy with locoregional treatment for synergistic effect
The Renji Hospital Interventional Oncology Team
Dr. Wang works within Renji Hospital's comprehensive interventional oncology program — one of China's highest-volume centers — alongside:
- Dr. Xu Aimin — Chief Physician with 35,000+ interventional procedures
- Dr. Shi Yaoping — Deputy Director specializing in comprehensive interventional treatment and translational research
This team structure means that complex cases — including HCC with PVTT — benefit from collective expertise and multidisciplinary discussion within one of China's most experienced interventional oncology departments.
How CMCS Coordinates Your Care
China Medical Concierge Shanghai (CMCS) is a health management company — not a hospital. We connect international patients with Shanghai's leading liver cancer specialists, including Dr. Wang Tao at Renji Hospital, and manage every step of the process:
- Review of existing liver imaging (MRI, CT), portal vein assessment, AFP and other tumor markers, liver function tests, and prior treatment records
- Treatment planning consultation with Dr. Wang's team for complex HCC with PVTT
- Coordination with hepatobiliary surgery, radiation oncology, and medical oncology for integrated multimodal planning
- Appointment scheduling with priority access
- Medical interpretation during consultations and procedures
- Logistics support: accommodation near Renji Hospital, visa assistance, and local transport
- Post-treatment follow-up and remote monitoring coordination
Get in Touch
If you have liver cancer with portal vein involvement or other complex presentations and are exploring treatment options in Shanghai, contact our team for a confidential consultation.
📧 contract@medicalsh.com
💬 WhatsApp: https://wa.me/message/3AM6KAGCW2BAD1
🌐 www.medicalsh.com
댓글 0개